BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2019;21:612-618. [PMID: 30366884 DOI: 10.1016/j.hpb.2018.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S, Pappagallo G, Seregni E, Versari A. Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers (Basel) 2022;14:2501. [PMID: 35626105 DOI: 10.3390/cancers14102501] [Reference Citation Analysis]
2 Kołat D, Kałuzińska Ż, Bednarek AK, Płuciennik E. Prognostic significance of AP-2α/γ targets as cancer therapeutics. Sci Rep 2022;12:5497. [PMID: 35361846 DOI: 10.1038/s41598-022-09494-1] [Reference Citation Analysis]
3 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Frey S, Mirallié E, Le Bras M, Regenet N. What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review. Cancers (Basel) 2021;13:5954. [PMID: 34885063 DOI: 10.3390/cancers13235954] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Modlin IM, Kidd M, Oberg K, Falconi M, Filosso PL, Frilling A, Malczewska A, Salem R, Toumpanakis C, Laskaratos FM, Partelli S, Roffinella M, von Arx C, Kudla BK, Bodei L, Drozdov IA, Kitz A. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Ann Surg Oncol 2021. [PMID: 34008138 DOI: 10.1245/s10434-021-10021-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hinterleitner M, Sipos B, Wagner V, Grottenthaler JM, Lauer UM, Zender L, Hinterleitner C. Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies. Cancers (Basel) 2021;13:2286. [PMID: 34064565 DOI: 10.3390/cancers13102286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
8 Pulvirenti A, Raj N, Cingarlini S, Pea A, Tang LH, Luchini C, Chou JF, Grego E, Marinova I, Capanu M, Landoni L, Scarpa A, Allen PJ, Klimstra DS, Reidy-Lagunes DL. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. Pancreas 2021;50:138-46. [PMID: 33565789 DOI: 10.1097/MPA.0000000000001740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Malczewska A, Oberg K, Kos-Kudla B. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocr Connect 2021;10:110-23. [PMID: 33289691 DOI: 10.1530/EC-20-0417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li D, Rock A, Kessler J, Ballena R, Hyder S, Mo C, Chang S, Singh G. Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinician's Guide to a Complex Illness. JCO Oncol Pract 2020;16:720-8. [PMID: 33085933 DOI: 10.1200/JCOOP.20.00010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Pulvirenti A, Pea A, Chang DK, Jamieson NB. Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. Front Med (Lausanne) 2020;7:385. [PMID: 32850899 DOI: 10.3389/fmed.2020.00385] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Mehta R, Lam-Chung CE, Hinojosa-Amaya JM, Roldán-Sarmiento P, Guillen-Placencia MF, Villanueva-Rodriguez G, Juarez-Leon OA, Leon-Domínguez J, Grajales-Gómez M, Ventura-Gallegos JL, León-Suárez A, Gómez-Pérez FJ, Cuevas-Ramos D. High Molecular Weight ACTH-Precursor Presence in a Metastatic Pancreatic Neuroendocrine Tumor Causing Severe Ectopic Cushing's Syndrome: A Case Report. Front Endocrinol (Lausanne) 2020;11:557. [PMID: 32903471 DOI: 10.3389/fendo.2020.00557] [Reference Citation Analysis]
13 Mpilla GB, Philip PA, El-Rayes B, Azmi AS. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World J Gastroenterol 2020; 26(28): 4036-4054 [PMID: 32821069 DOI: 10.3748/wjg.v26.i28.4036] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
14 Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol 2019;35:468-77. [PMID: 31306159 DOI: 10.1097/MOG.0000000000000571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 26] [Article Influence: 17.5] [Reference Citation Analysis]
16 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
17 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
18 Dhama K, Latheef SK, Dadar M, Samad HA, Munjal A, Khandia R, Karthik K, Tiwari R, Yatoo MI, Bhatt P, Chakraborty S, Singh KP, Iqbal HMN, Chaicumpa W, Joshi SK. Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values. Front Mol Biosci 2019;6:91. [PMID: 31750312 DOI: 10.3389/fmolb.2019.00091] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 27.7] [Reference Citation Analysis]
19 Faria SC, Sagebiel T, Patnana M, Cox V, Viswanathan C, Lall C, Qayyum A, Bhosale PR. Tumor markers: myths and facts unfolded. Abdom Radiol (NY) 2019;44:1575-600. [PMID: 30498924 DOI: 10.1007/s00261-018-1845-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]